Previous 10 | Next 10 |
BOSTON, MA / ACCESSWIRE / May 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Re...
Shares of Pieris Pharmaceuticals ( PIRS ) have fallen by 30% since my initial recommendation from August of 2017, where I highlighted management's partnering prowess as reflected in $4 billion in potential milestone payments the company stood to receive as multiple programs moved forward. Th...
Pieris Pharmaceuticals, Inc. (PIRS) Q1 2019 Results Earnings Conference Call May 10, 2019 08:00 AM ET Company Participants Allan Reine - Chief Financial Officer Stephen Yoder - CEO, President Louis Matis - Senior VP & Chief Development Officer Conference Call Participants ...
Pieris Pharmaceuticals ( PIRS ) Q1 results : Revenues: $8.5M (+102.4%). More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Pieris Pharmaceuticals (NASDAQ: PIRS ): Q1 GAAP EPS of -$0.20 misses by $0.02 . More news on: Pieris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company To Host An Investor Conference Call On Friday, May 10, 2019 At 8:00 AM EDT BOSTON, MA / ACCESSWIRE / May 10, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® tec...
BOSTON, MA / ACCESSWIRE / May 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced th...
Founded by a Nobel prize winner, Bicycle Therapeutics ( BCYC ) has developed a large amount of intangible assets, which should interest investors. Besides, the company reports collaboration agreements with larger pharmaceutical institutions, cash in hand, and no debt. While Bicycle is still at...
Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c...
BOSTON, MA / ACCESSWIRE / April 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan R...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-27 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...